A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis

Abstract

Anti‐tumour necrosis factor therapy is an established treatment for moderate‐to‐severely active ulcerative colitis (UC). Recent network meta‐analyses of controlled trial data have indicated a superiority of intravenous drugs (infliximab) over subcutaneous (adalimumab). We conducted a retrospective multi‐centre cohort study to determine the comparative effectiveness of these two drugs.